Clinical Trial Update: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating adding oral atogepant to onabotulinumtoxinA (Botox) in adults with chronic migraine to assess adverse events and changes in di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Atogepant (Atogepant)
• Botox (OnabotulinumtoxinA)

Snippet

Sponsor: AbbVie | Conditions: Chronic Migraine | Phase 3 | Status: COMPLETED